&nbsp;

HCP_Should-my-patients-start-on-a-biosimilar.pdf

Nov 2022

Document

HCP_Should-I-switch-a-patient-to-a-biosimilar.pdf

Nov 2022

Document

HCP_Should-my-patients-start-on-a-biosimilar_FR.pdf

Nov 2022

Document

HCP_Should-I-switch-a-patient-to-a-biosimilar_FR.pdf

Nov 2022

Statistical Reports

Prevention System Quality Index: Special Report on Cancer Prevention for People Living with Serious Mental Illness

Regimen

PC

Cancer Type:

Central Nervous System

Intent: Adjuvant, Curative, Palliative

Funding:

ODB - General Benefit

procarbazine

ODB - General Benefit

lomustine

Drugs Used:

lomustine,

procarbazine

Quick Link(s):

Regimen Monograph

Jan 2023

Regimen

PACL+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

PACL(W)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

PACL(DD)+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Document

PEBCBiodegradableRectalSpacersforProstateCancerRadiotherapy.pdf

Mar 2023

Document

PolicyRectalSpacersImplementationGuidanceDocumentProstateCancerPatientsOntario.pdf

Mar 2023

Document